The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease

被引:34
|
作者
Engelmann, Cornelius [1 ,2 ,3 ,4 ]
Tacke, Frank [1 ,2 ]
机构
[1] Charite Univ Med Berlin, Campus Virchow Klinikum CVK, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany
[2] Charite Univ Med Berlin, Campus Charite Mitte CCM, D-13353 Berlin, Germany
[3] Berlin Inst Hlth BIH, D-10178 Berlin, Germany
[4] UCL, Inst Liver & Digest Hlth, London NW3 2PF, England
关键词
NAFLD; NASH; SASP; senescence associated secretory phenotype; mitochondrial dysfunction; fibrosis; HEPATIC STELLATE CELLS; EXPERIMENTAL NASH; FIBROSIS; DYSFUNCTION; PROGRESSION; ACTIVATION; STEATOHEPATITIS; INFLAMMATION; HEPATOCYTES; MARKER;
D O I
10.3390/ijms23020652
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) represents an increasing global health burden. Cellular senescence develops in response to cellular injury, leading not only to cell cycle arrest but also to alterations of the cellular phenotype and metabolic functions. In this review, we critically discuss the currently existing evidence for the involvement of cellular senescence in NAFLD in order to identify areas requiring further exploration. Hepatocyte senescence can be a central pathomechanism as it may foster intracellular fat accumulation, fibrosis and inflammation, also due to secretion of senescence-associated inflammatory mediators. However, in some non-parenchymal liver cell types, such as hepatic stellate cells, senescence may be beneficial by reducing the extracellular matrix deposition and thereby reducing fibrosis. Deciphering the detailed interaction between NAFLD and cellular senescence will be essential to discover novel therapeutic targets halting disease progression.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Rockstroh, Juergen Kurt
    CURRENT HIV/AIDS REPORTS, 2017, 14 (02) : 47 - 53
  • [32] Evolutionary conservation of long non-coding RNAs in non-alcoholic fatty liver disease
    Rohilla, Sumati
    Awasthi, Ankita
    Kaur, Savneet
    Puria, Rekha
    LIFE SCIENCES, 2021, 264
  • [33] Transient elastography in non-alcoholic fatty liver disease
    Abenavoli, Ludovico
    Beaugrand, Michel
    ANNALS OF HEPATOLOGY, 2012, 11 (02) : 172 - 178
  • [34] The Natural Course of Non-Alcoholic Fatty Liver Disease
    Bertot, Luis Calzadilla
    Adams, Leon Anton
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (05)
  • [35] Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease
    Mitten, Emilie K.
    Baffy, Gyorgy
    JOURNAL OF HEPATOLOGY, 2022, 77 (06) : 1642 - 1656
  • [36] Natural history of non-alcoholic fatty liver disease
    Pais, R.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2022, 26 (03): : 88 - 92
  • [37] Non-alcoholic fatty liver disease and childhood obesity
    Shaunak, Meera
    Byrne, Christopher D.
    Davis, Nikki
    Afolabi, Paul
    Faust, Saul N.
    Davies, Justin Huw
    ARCHIVES OF DISEASE IN CHILDHOOD, 2021, 106 (01) : 3 - 8
  • [38] Non-alcoholic fatty liver disease: pathogenesis and models
    Zhong, Hanxiang
    Dong, Jiayong
    Zhu, Liye
    Mao, Jiaxi
    Dong, Junfeng
    Zhao, Yuanyu
    Zou, You
    Guo, Meng
    Ding, Guoshan
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (02): : 387 - 399
  • [39] Discussing the role of circular RNA in the pathogenesis of non-alcoholic fatty liver disease and its complications
    Yepmo, Melissa
    Potier, Jean-Baptiste
    Pinget, Michel
    Grabarz, Anastasia
    Bouzakri, Karim
    Bourie, Auror Dumond
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [40] A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
    Tilg, Herbert
    Effenberger, Maria
    Adolph, Timon E.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 103 - 106